
New Products
Thromboteck PSe, LupoTek DetecTin VL,
and LupoTek CorrecTin VL
See below for more details.
__________________________________________
THROMBOTEK PSe
Clotting Assay for Quantification of Protein S Activity
Product # 90-480
· Complete kit for the quantitative determination of Protein S activity in human plasma.
· Performed as a simple factor assay. Suitable for manual and fully automated methods.
· Precision: 4.9% repeatability, 5.7% total imprecision for normal plasma
7.8% repeatability, 9.2% total imprecision for abnormal plasma
· Linearity: 10% PS to 156% PS (maximum tested)
· Lower limit of detection: 1% Protein S activity
· Reconstituted stability: 24 hour 2-8°C
8 hour RT
· Typical calibration data (AMAX 200):
|
Calibrator Standard (Actual %) |
PSe Lot PS0130 clot time, sec |
PSe Lot PS0140 clot time, sec |
PSE Lot PS0150 clot time, sec |
|
156.00% |
131.6 |
120.2 |
125.5 |
|
117.00% |
114.1 |
103.0 |
106.9 |
|
78.00% |
98.9 |
89.9 |
92.0 |
|
39.00% |
81.9 |
73.5 |
74.3 |
|
19.50% |
72.1 |
64.6 |
64.3 |
|
10.00% |
66.3 |
60.3 |
59.5 |
|
5.00% |
63.2 |
57.0 |
56.0 |
|
|
|
|
|
|
r squared |
0.997 |
0.998 |
0.998 |
|
slope |
44.6 |
41.0 |
45.1 |
|
intercept |
62.7 |
56.4 |
55.3 |
![]() |
Click Here to View Product Insert
__________________________________________________________
LupoTek DetecTin VL
and LupoTek CorrecTin VL
r2 Diagnostic's new venom screen and confirm reagents for detection of Lupus Anticoagulants.
LupoTek DetecTin VL Product # 85-202
LupoTek CorrecTin VL Product # 86-201
· LupoTek DetecTin VL and CorrecTin VL use Vipera lebetina (VLV) venom rather than
Vipera russelli (RVV) venom.
· VLV activates FX to FXa via the same mechanism as RVV.
· Using VLV is more eco-friendly than using RVV.
· LupoTek DetecTin VL and CorrecTin VL demonstrated sensitivity of 100% and specificity of
100% with a normalized ratio of 1.30 in a 122 patient cut-off study.
· LupoTek DetecTin VL and CorrecTin VL demonstrated 98% positive agreement, 96% negative
agreement, and 97% overall agreement with dRVV reagents in a 155 patient, multi-site study.
*r2 is a U.S. manufacturer and is the owner of its VLV intellectual property*
Click Here to View Product Insert